TAmiRNA collaboration with Vivomicx aims for new model RNA expression
Press Release | TAmiRNA GmbH
MARCH 22, 2018
Vienna, Austria: Biotech innovators TAmiRNA has joined forces with Netherlands-based Vivomicx to target new forms of RNA expression analysis.
The companies believe that combining TAmiRNA’s mastery of identifying and validating non-coding RNAs as biomarkers with Vivomicx’s technologies for in-vivo molecular pathology and pharmacology can produce synergies that will unlock cell-type specific RNA expression analysis in complex tissues.
Advanced drug characterization
“This advanced form of analysis can then be applied to form better understanding of drug mode of actions along with corresponding improvement in discovery and characterization of lead drug candidates,” said TAmiRNA CEO, Dr. Matthias Hackl.
The companies say their combined technologies could also produce advances in:
- Quantification of drug-target engagement in specific cell types in complex tissue
- Characterization of differences between malignant and benign tissue
- Novel biomarkers for patient selection
TAmiRNA and Vivomicx appeared together at the two-day RNA Therapeutics Conference in London, on February 21-22, 2018.
Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.
TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.
TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer, which aim to provide ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular disease (thrombomiR).
TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.
More information available at: www.tamirna.com.
Vivomicx is a biotechnology company based at Groningen in the Netherlands that is dedicated to advanced molecular pathology and pharmacology; particularly the study of cells in their in vivo (patho) physiological environment.
In October 2006, the commercial entity Vivomicx was registered at the Chamber of Commerce in Groningen as the result of an academic initiative aimed at making the drug discovery process more efficient, grant funded by the Dutch government STW foundation for Technology & Science.
In July 2008 a follow-up project was granted that enabled execution of a proof of concept study in order to further expand application of the Vivomicx technology. This was supported by two leading companies who wished to see clinical compounds tested using Vivomicx technology. This allows prediction of the effects of a new drug on the gene expression profiles of subsets of cells in the organ where the disease is located; either target cells for desired effects of the drug or non-target cells to study side effects of undesired toxicity.
Vivomicx also specializes in identifying real biomarkers for drug efficacy to speed up the development process.
Further information at: http://vivomicx.eu.
Dr. Elisabeth Schraml, Scientific Communications, TAmiRNA GmbH
Tel: +43 (0)660 420 58 56